Jump to content

MYC: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
BOTijo (talk | contribs)
m {{R from other capitalisation}}
created gene specific article from redirect
Tag: Removed redirect
Line 1: Line 1:
{{Infobox_gene}}
#REDIRECT [[Myc]] {{R from other capitalisation}}

'''MYC proto-oncogene, bHLH transcription factor''' is a [[protein]] that in humans is encoded by the MYC [[gene]].
<ref name="entrez">
{{cite web
| title = Entrez Gene: MYC proto-oncogene, bHLH transcription factor
| url = http://www.ncbi.nlm.nih.gov/gene/4609
| accessdate = 2020-03-02
}}</ref>

==Function==

This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The encoded protein forms a heterodimer with the related transcription factor MAX. This complex binds to the E box DNA consensus sequence and regulates the transcription of specific target genes. Amplification of this gene is frequently observed in numerous human cancers. Translocations involving this gene are associated with Burkitt lymphoma and multiple myeloma in human patients. There is evidence to show that translation initiates both from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site, resulting in the production of two isoforms with distinct N-termini. [provided by RefSeq, Aug 2017].

== References ==

{{reflist}}

== Further reading ==

{{refbegin | 2}}
*{{cite journal |vauthors=Hann SR, King MW, Bentley DL, Anderson CW, Eisenman RN |title=A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas |journal=Cell |volume=52 |issue=2 |pages=185–95 |date=January 1988 |pmid=3277717 |doi=10.1016/0092-8674(88)90507-7 |url=}}
*{{cite journal |vauthors=Hiyama T, Haruma K, Kitadai Y, Ito M, Masuda H, Miyamoto M, Tanaka S, Yoshihara M, Sumii K, Shimamoto F, Chayama K |title=c-myc gene mutation in gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma |journal=Oncol. Rep. |volume=8 |issue=2 |pages=289–92 |date=2001 |pmid=11182042 |doi=10.3892/or.8.2.289 |url=}}
*{{cite journal |vauthors=Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, Sample JT |title=EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma |journal=Curr. Top. Microbiol. Immunol. |volume=258 |issue= |pages=153–60 |date=2001 |pmid=11443860 |doi=10.1007/978-3-642-56515-1_10 |url=}}
*{{cite journal |vauthors=Hu HM, Arcinas M, Boxer LM |title=A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma |journal=J. Biol. Chem. |volume=277 |issue=12 |pages=9819–24 |date=March 2002 |pmid=11777933 |doi=10.1074/jbc.M111426200 |url=}}
*{{cite journal |vauthors=Hilker M, Tellmann G, Buerke M, Moersig W, Oelert H, Lehr HA, Hake U |title=Expression of the proto-oncogene c-myc in human stenotic aortocoronary bypass grafts |journal=Pathol. Res. Pract. |volume=197 |issue=12 |pages=811–6 |date=2001 |pmid=11795828 |doi=10.1078/0344-0338-00164 |url=}}
*{{cite journal |vauthors=Feng XH, Liang YY, Liang M, Zhai W, Lin X |title=Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B) |journal=Mol. Cell |volume=9 |issue=1 |pages=133–43 |date=January 2002 |pmid=11804592 |doi=10.1016/s1097-2765(01)00430-0 |url=}}
*{{cite journal |vauthors=Geick A, Redecker P, Ehrhardt A, Klocke R, Paul D, Halter R |title=Uteroglobin promoter-targeted c-MYC expression in transgenic mice cause hyperplasia of Clara cells and malignant transformation of T-lymphoblasts and tubular epithelial cells |journal=Transgenic Res. |volume=10 |issue=6 |pages=501–11 |date=December 2001 |pmid=11817538 |doi=10.1023/a:1013085228119 |url=}}
*{{cite journal |vauthors=Kuschak TI, Kuschak BC, Taylor CL, Wright JA, Wiener F, Mai S |title=c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene |journal=Oncogene |volume=21 |issue=6 |pages=909–20 |date=January 2002 |pmid=11840336 |doi=10.1038/sj.onc.1205145 |url=}}
*{{cite journal |vauthors=Chettab K, Zibara K, Belaiba SR, McGregor JL |title=Acute hyperglycaemia induces changes in the transcription levels of 4 major genes in human endothelial cells: macroarrays-based expression analysis |journal=Thromb. Haemost. |volume=87 |issue=1 |pages=141–8 |date=January 2002 |pmid=11848444 |doi= |url=}}

{{refend}}


{{gene-8-stub}}
{{NLM content}}

Revision as of 09:29, 2 March 2020

MYC
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesMYC, MRTL, MYCC, bHLHe39, c-Myc, v-myc avian myelocytomatosis viral oncogene homolog, MYC proto-oncogene, bHLH transcription factor, Genes, myc, c-myc
External IDsOMIM: 190080; MGI: 97250; HomoloGene: 31092; GeneCards: MYC; OMA:MYC - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_002467
NM_001354870

NM_001177352
NM_001177353
NM_001177354
NM_010849

RefSeq (protein)

NP_002458
NP_001341799

NP_001170823
NP_001170824
NP_001170825
NP_034979

Location (UCSC)Chr 8: 127.74 – 127.74 MbChr 15: 61.86 – 61.86 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

MYC proto-oncogene, bHLH transcription factor is a protein that in humans is encoded by the MYC gene. [5]

Function

This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The encoded protein forms a heterodimer with the related transcription factor MAX. This complex binds to the E box DNA consensus sequence and regulates the transcription of specific target genes. Amplification of this gene is frequently observed in numerous human cancers. Translocations involving this gene are associated with Burkitt lymphoma and multiple myeloma in human patients. There is evidence to show that translation initiates both from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site, resulting in the production of two isoforms with distinct N-termini. [provided by RefSeq, Aug 2017].

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000136997Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000022346Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ "Entrez Gene: MYC proto-oncogene, bHLH transcription factor". Retrieved 2020-03-02.

Further reading

  • Hann SR, King MW, Bentley DL, Anderson CW, Eisenman RN (January 1988). "A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas". Cell. 52 (2): 185–95. doi:10.1016/0092-8674(88)90507-7. PMID 3277717.
  • Hiyama T, Haruma K, Kitadai Y, Ito M, Masuda H, Miyamoto M, Tanaka S, Yoshihara M, Sumii K, Shimamoto F, Chayama K (2001). "c-myc gene mutation in gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma". Oncol. Rep. 8 (2): 289–92. doi:10.3892/or.8.2.289. PMID 11182042.
  • Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, Sample JT (2001). "EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma". Curr. Top. Microbiol. Immunol. 258: 153–60. doi:10.1007/978-3-642-56515-1_10. PMID 11443860.
  • Hu HM, Arcinas M, Boxer LM (March 2002). "A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma". J. Biol. Chem. 277 (12): 9819–24. doi:10.1074/jbc.M111426200. PMID 11777933.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  • Hilker M, Tellmann G, Buerke M, Moersig W, Oelert H, Lehr HA, Hake U (2001). "Expression of the proto-oncogene c-myc in human stenotic aortocoronary bypass grafts". Pathol. Res. Pract. 197 (12): 811–6. doi:10.1078/0344-0338-00164. PMID 11795828.
  • Feng XH, Liang YY, Liang M, Zhai W, Lin X (January 2002). "Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B)". Mol. Cell. 9 (1): 133–43. doi:10.1016/s1097-2765(01)00430-0. PMID 11804592.
  • Geick A, Redecker P, Ehrhardt A, Klocke R, Paul D, Halter R (December 2001). "Uteroglobin promoter-targeted c-MYC expression in transgenic mice cause hyperplasia of Clara cells and malignant transformation of T-lymphoblasts and tubular epithelial cells". Transgenic Res. 10 (6): 501–11. doi:10.1023/a:1013085228119. PMID 11817538.
  • Kuschak TI, Kuschak BC, Taylor CL, Wright JA, Wiener F, Mai S (January 2002). "c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene". Oncogene. 21 (6): 909–20. doi:10.1038/sj.onc.1205145. PMID 11840336.
  • Chettab K, Zibara K, Belaiba SR, McGregor JL (January 2002). "Acute hyperglycaemia induces changes in the transcription levels of 4 major genes in human endothelial cells: macroarrays-based expression analysis". Thromb. Haemost. 87 (1): 141–8. PMID 11848444.


This article incorporates text from the United States National Library of Medicine, which is in the public domain.